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Introduction
Spinal cord injury (SCI) is a life changing event that has a 
substantial impact on the individual’s physical and mental 
health. A global annual incidence of 8.0 to 246.0 cases 
per million inhabitants has been reported1 with an increase 
in the percentage of cases of tetraplegia and complete 
lesions over a 20 years period (1994-2013)2,3. People with 
SCI experience secondary medical complications such as 
those affecting their body composition4,5. They experience 
extensive declines in bone density and strength that put them 
at high risk of fragility fractures and associated morbidity 
and mortality6.
This review article summarises different aspects of 
bone loss and osteoporosis after SCI. It discusses the 
factors that have been shown to contribute to the SCI-
induced bone loss and describes in detail how bone loss 
develops in the acute and chronic phases of the injury 
until it reaches its steady state. Factors influencing the 
large inter-site and inter-individual patterns of bone 
loss observed in individuals with SCI are also described, 
in addition to clinical consequences e.g. fractures from 
SCI-related bone loss and associated complications. 
It also reviews different physical and pharmacological 
interventions that have been tested in patients with SCI, to 
investigate their effectiveness in reversing or attenuating 
bone loss in acute and chronic phases respectively. 
Abstract
Osteoporosis is a long-term consequence of spinal cord injury (SCI) that leads to a high risk of fragility fractures. The 
fracture rate in people with SCI is twice that of the general population. At least 50% of these fractures are associated 
with clinical complications such as infections. This review article presents key features of osteoporosis after SCI, starting 
with its aetiology, a description of temporal and spatial changes in the long bones and the subsequent fragility fractures. 
It then describes the physical and pharmacological approaches that have been used to attenuate the bone loss. Bone loss 
after SCI has been found to be highly site-specific and characterised by large inter-variability and site-specific changes. 
The assessment of the available interventions is limited by the quality of the studies and the lack of information on their 
effect on fractures, but this evaluation suggests that current approaches do not appear to be effective. More studies are 
required to identify factors influencing rate and magnitude of bone loss following SCI. In addition, it is important to test 
these interventions at the sites that are most prone to fracture, using detailed imaging techniques, and to associate bone 
changes with fracture risk. In summary, bone loss following SCI presents a substantial clinical problem. Identification of 
at-risk individuals and development of more effective interventions are urgently required to reduce this burden.
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Aetiology of bone loss after SCI
The type of osteoporosis that develops after spinal cord 
injury (SCI) has been reported to be induced by a combination 
of factors. The main causal factor is understood to be from 
mechanical unloading7, that has also been evidenced by the 
reported bone loss following space flights and bed rest8,9. In 
addition, neuronal and hormonal changes have been found to 
contribute to its pathogenesis7.
Unloading and the bone formation-resorption imbalance
SCI causes immediate disuse and a subsequent loss 
of biomechanical stress on bones, which is a substantial 
stimulus for the bone remodelling process controlled by 
osteocytes7,8,10. This absence of mechanical loading leads 
to an adaptive response involving inhibition of osteoblastic 
bone formation and increases in osteoclastic bone resorption 
resulting in demineralisation. In some cases, the imbalance 
between bone formation and resorption is so great and 
sustained that it leads to severe bone loss. 
This has been widely documented in both acute and chronic 
SCI. Bone resorption biochemical markers in blood and urine, 
such as total deoxypyridinoline (DPD) ,N-telopeptide (NTx), 
serum and urinary type I collagen C-telopeptide (CTx) and 
hydroxyproline have been found to be significantly increased 
in acute and chronic SCI11-14, but significantly lower in chronic 
than in acute SCI14. Nonetheless, elevated levels of DPD were 
evident in 30% of patients 10 years or more after injury15. 
This significant rise in bone resorption rate after SCI has been 
found to be associated with a slight increase in osteoblastic 
bone formation activity, evidenced by minor increases in 
serum osteocalcin and total alkaline phosphatase11. However, 
there is no consensus on the significance of these small 
increases in osteoblastic activity, which were found to be 
minor in some studies11 but substantial in others12,16. 
The increase in bone resorption and the associated 
calcium efflux from bones after SCI leads to abnormally high 
concentrations of calcium in blood (hypercalcemia)17 and 
urine (hypercalciuria)18,19. 
Neurovascular changes
Bone also undergoes neurovascular changes caused 
by the neurological lesion and the subsequent disturbance 
of bone tissue innervation7. Whilst it is clear that the loss 
of motor function and the associated reduction in bone 
loading caused by neural damage contribute substantially to 
bone loss following SCI, the contribution of other neurally-
mediated mechanisms of bone loss is less clear20. Some of 
the neuronal changes are directly caused by the significant 
reduction in sensory and autonomic nerve fibres and nerve-
derived factors (neuropeptides) which have been documented 
to regulate and modulate bone metabolism7,21,22. 
The autonomic nervous system has been documented 
to regulate skeletal metabolism through different 
pathways23,24. Increased activity of the sympathetic nervous 
system is known to suppress bone formation and favour 
bone resorption23. Subsequently, one would expect that the 
attenuated sympathetic activity after SCI should increase 
bone mass instead. It is clear that the extensive bone loss 
that occurs after SCI cannot be explained directly by the 
attenuated sympathetic activity25. Furthermore, interruption 
to the sympathetic system and the subsequent vasomotor 
irregularity can better (and in part) explain the loss in bone 
mass26. The interrupted sympathetic nerves (which have 
their processes distributed along bone vessels27), lead to 
vascular modification in the sub-lesional areas7,28. Changes 
in bone blood flow after SCI have been evidenced by high 
intramedullary pressure and arteriovenous shunting in the 
legs leading to venous stasis and adverse consequences 
for bone metabolism16,29. The effect of the reduced 
parasympathetic activity after SCI30 is an area of active 
research, and our understanding of its role in regulating 
bone metabolism is currently limited23,25, which further 
emphasises the multi-factorial and complex aetiology of 
bone loss after SCI. 
Hormonal changes
Hypercalciuria is prevalent in the acute phase of SCI 
as a result of the abnormally high ionised calcium levels 
which are found to get back to normal during the chronic 
phase31. These changes (in the acute phase) are followed 
by changes in calcium regulatory hormone levels. Serum 
intact parathyroid hormone (iPTH) level was found to be 
suppressed in acute and sub-acute SCI as expected for this 
negative feedback loop (1-4 months)11-13,32. It increases in 
the chronic phase compared to the acute phase but it stays 
within or below the lower reference ranges31. Only one study 
reported a decreased level of PTH in the chronic phase, which 
was associated with normal ionised calcium levels18. This 
decline in PTH has been suggested in this study to be driven 
by “low-grade increased calcium release”, which in turn 
indicates persistently elevated bone resorption even after 
years of injury18, a hypothesis that is also supported by the 
high levels of bone resorption markers reported during the 
chronic phase31. 
Reported changes in vitamin D levels in acute SCI, show 
reduced levels of 1,25(OH)
2
 vitamin D (the biologically 
active form of vitamin D), as a result of bone resorption 
and the suppression of PTH13,32. However, different results 
were reported for 25-hydroxyvitamin D (25(OH)D) in the 
acute phase: with one study reporting normal32, and others 
reporting low levels33,34. Using different reference values 
to define normal levels of vitamin D level and other factors 
such as ethnicity and season might have contributed to this 
variability in their results. In people with chronic SCI, low 
levels of 25-hydroxyvitamin D (25(OH)D) have been found 
to be prevalent34-36, which might be accompanied by mild 
secondary hyperthyroidism37. This could be due to limited 
exposure to sunlight, prescription of medications that 
increase vitamin D metabolism and, perhaps, restricted dairy 
intake36. Only one study reported normal levels of 25(OH)
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D in the chronic phase, which was explained by the majority 
of medically stable and active participants included in this 
study18. 
SCI is associated with severe muscle atrophy affecting 
the sublesional areas38,39 within the first few days after 
injury40,41. About one third reduction in thigh muscle cross 
sectional area (CSA) has been found to occur within only 6 
to 24 weeks postinjury40,42. The denervation and atrophy 
of these muscles (alongside other factors such as reduced 
physical activity) are believed to be one of the determinants 
of insulin resistance5, which is also associated with increased 
intra-muscular fat in people with SCI43. 
Sex hormones also play a major role in regulating 
bone metabolism. Oestrogen has been shown to prevent 
osteocyte apoptosis44, and both oestrogen and androgen 
inhibit bone resorption and promote bone formation via 
many mechanisms45,46. SCI causes the inhibition of sex 
hormone production and secretion7. In people with acute 
SCI, testosterone levels were significantly lower than in the 
uninjured control group, with no further change after week 
16 post injury13.
 When investigating hypothalamus-pituitary-ovary and 
hypothalamus-pituitary-thyroid axes in women with SCI, 
approximately 80% women were found to have at least one 
axis abnormality47. These findings suggest that bone loss can 
be linked to impaired endocrine function in people with SCI.
Structural and geometric changes in bone  
after SCI
Densitometric assessment of bone parameters after SCI
Most of the studies on bone loss in the early acute phase 
and throughout the chronic phase following SCI, have used 
medical imaging technologies such as dual-energy x-ray 
absorptiometry (DXA) and peripheral quantitative computed 
tomography (pQCT).
DXA enables scanning of sites that are generally the 
most susceptible to osteoporotic fractures in the general 
population such as the vertebrae and proximal femur (hips) 
and wrist48, aiding in detection of osteoporosis and reducing 
the risk of such clinically and economically costly fractures49.
Furthermore, its low radiation dose, low price, wide 
availability and ease of use have all made it the predominantly 
used technique to diagnose osteoporosis49,50 and assess 
susceptibility to fractures clinically51. For similar reasons, it 
has been the default densitometric technique for measuring 
bone density in clinical trials50 to evaluate the effectiveness 
of interventions. 
However, DXA measures areal BMD, which is highly 
affected by bone size, leading to larger bones appearing to 
have a greater density than smaller bones49 resulting in both 
bone loss and fracture risk being underestimated52. DXA’s 
inability to extract three-dimensional measurements of bone 
geometry limits its utility in describing detailed components 
of bone structure relevant to fracture risk49,53. Moreover, 
DXA does not distinguish between trabecular and cortical 
compartments49. This limitation of DXA is particularly relevant 
in disuse osteoporosis due to the differences in the extent and 
time-course of bone loss in these two bone compartments.
There is good evidence that, in people with SCI, 
trabecular bone has a more rapid response to disuse15,54-56 
and interventions51 compared to cortical bone (when 
considering the percentage of the loss in bone). Therefore, 
it is recommended to obtain separate, detailed trabecular 
and cortical BMD measurements in order to assess the 
effectiveness of different bone interventions. 
pQCT and high resolution pQCT (HR-pQCT) provide 
detailed volumetric parameters of trabecular and cortical 
compartments57 making these techniques clinically relevant 
for this population. They assess volumetric density (vBMD) 
that considers bone depth (BMC/cm3)51 and quantify both 
hard and soft tissues within the region of interest53. pQCT 
also allows detailed, site-specific examination of regions 
such as the distal femur and proximal tibia58. These areas 
are particularly prone to fracture in individuals with SCI, who 
lose bone mass exclusively in sublesional sites56 as shown in 
Figure 1. In contrast, the most commonly performed regional 
DXA scans focus on the proximal femur and the lumbar spine. 
HR-pQCT acquires 3D images of bone microarchitecture 
which is of importance in assessing bone strength in individuals 
who are susceptible to fractures49,58, especially people with 
SCI57. It provides trabecular and cortical parameters such as 
trabecular number, separation, anisotropy and trabecular 
and cortical thickness49, shown to improve fracture risk 
prediction59,60.
Despite their capabilities, these techniques impose certain 
practical constraints as imaging of patients with bilateral 
metal implants or spasticity that could cause movement 
artefacts is challenging61. HR-pQCT can only be used to 
scan peripheral sites such as distal radius and tibia due to 
its small field of view, which is compromised to achieve 
the optimum resolution58. Moreover, the 140 mm gantry 
diameter makes it unusable for scanning obese patients or 
regions such as the thigh and proximal femur61. Nevertheless, 
these techniques offer detailed bone microarchitecture 
measurements for people with SCI, who are of higher risk 
of sustaining osteoporotic fractures mostly in their lower 
extremities, compared to the spine and upper extremities 
that are less prone to fracture57,62. Bone loss after SCI occurs 
at sublesional sites only, leading to upper limb bone health 
being preserved in people with paraplegia whilst people with 
tetraplegia are at risk of developing osteoporosis in both the 
upper and lower limbs63,64.
Notwithstanding the substantial advantages that pQCT 
and HR-pQCT offer over DXA, they are not currently 
recommended to be used routinely by clinicians in the 
diagnosis of osteoporosis, fracture risk prediction or 
assessment of bone conditions treatments. This is due to 
the lack of international standards that regulate its clinical 
use with regards to aspects such as scanning and analysis 
protocols and anatomical sites, which were recommended 
recently by Cervinka et al65. 
The absence of standards for the clinical use of pQCT, 
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combined with the ready availability of DXA machines in 
clinics has driven the development of protocols to make DXA 
scans more clinically relevant to people with SCI. Different 
DXA protocols and software have been developed and 
validated to acquire and analyse images at the knee region, 
which until now has not been a standard measurement site in 
DXA. Methods that extract sub-regions from total body DXA 
scan are not recommended due to their poor repeatability 
and image resolution66. A commercially available GE lunar 
software for the knee region has FDA approval and is being 
used for both clinical and research purposes67-69. Few studies 
investigated the accuracy of conventional DXA software 
designed for lumbar spine, proximal femur and forearm, 
in predicting BMD and fracture risk at the knee70,71. A DXA 
forearm software has been validated by McPherson et al. 
(2014) to be used to measure BMD at the knee in people with 
SCI72. It was found to be accurate in short-term assessments 
and has been proposed as a reliable method to assess BMD 
at the distal femur and proximal tibia using DXA in clinical 
trials71. The International Society of Clinical Densitometry 
recommended a BMD analysis protocol based on lumbar 
spine software for the calculation of BMD at the knee66,73, 
until knee-specific software is developed. There remains 
the need for valid manufacturer-adopted knee software to 
accurately measure BMD at the distal femur and proximal 
tibia for clinical use66.
Time course of bone changes after SCI 
Many longitudinal studies on people with SCI emphasise 
the substantial effect of time since injury on bone structural 
and geometric parameters during both the acute (5 weeks-12 
months)74 and the chronic phases75. Bone resorption markers 
have been shown to increase significantly to maximum 
levels within 10-16 weeks postinjury11. In the same study, 
BMD losses in the lower limbs were detected at follow-up 
(24th week postinjury)11. Bone mass continues to decrease 
with time throughout the first 8 months76, 12 months74, 2 
years77 and even throughout the chronic phase (up to 19-25 
years)78,79 but at a slower rate in the later phases compared 
to the rapid loss during acute phase54. However, some studies 
found that bone loss reaches steady-state phase at 3-8 years 
postinjury depending on the bone parameter measured55,75 
with about 50% and 60% loss in bone mass in the femoral 
and tibial epiphyses, and 35% and 25% in the femoral and 
tibial shafts respectively55. Determining the time course of 
the adaptive modifications in bone geometry and structure is 
of clinical importance to assess the effectiveness of different 
rehabilitation interventions in reversing bone loss75.
Patterns and time course of loss in cortical and trabecular 
compartments
Bone loss at epiphyseal sites (which are rich in trabecular 
bone) has been attributed to the decline in trabecular BMD 
with comparatively little loss from the outer cortical shell80. In 
contrast, bone loss at diaphyseal sites composed primarily of 
cortical bone is suggested to be characterised by a reduction 
in wall thickness via endocortical resorption in addition to 
smaller decreases in cortical BMD15,53,81 as shown in Figure 2. 
Exponential decreases in bone parameters with time 
postinjury (2 months to 50 years) have been described 
using pQCT, specifically in bone mass, total and trabecular 
BMD (BMDtot and BMDtrab, respectively) of the femoral and 
tibia epiphyses, as well as bone mass and cortical CSA of 
the diaphysis as shown in Figure 155. In a longitudinal study 
using pQCT scans, significant decline in cortical BMD and 
cross sectional area (CSA) has been reported alongside the 
epiphyseal changes within the first 12 months postinjury74. In 
the acute phase, tibial and femoral cortical BMD losses make 
a substantial contribution to bone loss at these diaphyseal 
sites74. It has been suggested that acute cortical BMD losses 
may be transient, resulting from increased remodelling 
in the early stages post-injury55. Indeed, in the chronic 
phase cortical bone losses at these sites appear primarily 
attributable to decreased cortical bone cross-sectional 
area with little or no contribution of BMD losses reported55. 
Nevertheless, the loss in trabecular BMD seems to occur at 
a more rapid rate acutely and is of greater magnitude in the 
chronic phase than that in the cortical bone55,82 as shown in 
Figure 1. Lower BMD in the proximal femur6,79,83, femoral 
shaft and lumbar spine83 have also been correlated with time 
since injury. 
Characteristic temporal and site-specific patterns
Acute SCI 
During acute SCI (measured between week 8 and 12 
months postinjury), DXA reveals significantly lower BMD 
in the lower limbs11,13, total body, pelvis13, proximal femur14, 
midshaft and distal femur84 with no difference in the hip 
(between week 8 and week 24 postinjury11, although BMD 
loss might have been detected sooner than 24 weeks if the 
protocol had allowed it), lumbar spine or radius11,13,14. After 
only one year postinjury the distal femur and proximal tibia 
lost up to 52% and 70% of their BMD respectively64.
pQCT scans during this phase showed a significant decline 
in tibial trabecular BMD (at 6 and 12 months) as well as in 
cortical BMD (only at 12 months)74,85. Other epiphyseal (BMC, 
total BMD) and diaphyseal (BMC, cortical CSA) parameters of 
the tibia and femur bones also decreased74. Lower trabecular 
BMD was reported in the radius and ulna (at 6 & 12 months) 
and cortical BMD (at 12 months) in people with tetraplegia 
with no differences detected at these sites in those with 
paraplegia85. pQCT results in acute SCI further emphasise 
the rapid rate of trabecular loss compared to cortical loss. 
Chronic SCI
Significant decreases in BMD and BMC have been 
documented at the distal femur86-88, proximal tibia86,87,89 
proximal femur14,90, femoral neck54,87,88,91,92, femoral 
shaft87 and total femur88. This BMD loss seemingly 
occurs in the lumbar spine as well52,93, but was previously 
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Figure 1. Differences in trabecular (upper row) and cortical (lower row) BMD with time (2 months to 50 years) postinjury in the femur 
(a,d), tibia (b,e) and radial (c,f) bones within a group of individuals with SCI-induced paraplegia ( 0 ) and tetraplegia (x)55. (Reproduced 
with permission).
Figure 2. (Left): compares volumetric BMC at different sites along the tibia (starting from distal tibia at 5% of the tibial length and moving 
toward the proximal epiphysis in steps of 5% (up to 95% of the tibia length) between controls and participants with SCI. It also shows the 
more pronounced bone loss at the epiphyses compared to the diaphysis between the two groups. (Right): shows pQCT images of the tibia 
distal epiphysis (left column) and diaphysis (right column) in an uninjured control (upper row) and an individual with SCI (lower row). The 
decrease in trabecular BMD and the cortical thinning at epiphysis can be seen clearly, alongside the cortical loss/trabecularisation in the 
diaphysis80. (Reproduced with permission).
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undetectable by conventional DXA14,94. This was likely 
due to an overestimate of bone mass resulting from 
neuropathic calcification and other skeletal abnormalities 
in the vertebrae of people with SCI52.
pQCT scans in people with paraplegia revealed significantly 
lower tibial total BMD80,82, trabecular BMD, cortical BMD, 
and cortical thickness, as shown in Figure 2, alongside 
similar periosteal and increased endosteal circumferences82 
compared to controls. These findings in cortical parameters 
further confirm the proposed mechanism of cortical thinning 
by endocortical resorption55.
BMD and BMC at the distal and proximal tibia epiphyses77,90 
and in the patella have been reported to be significantly 
less than those in controls. Sabo et al. reported that the 
cortical area at the distal femur and proximal tibia was lower 
than that in controls but no difference in cortical BMD was 
reported in this study90. The loss in volumetric BMC was 
more pronounced at the distal and proximal tibia than in the 
diaphysis77,82.
Factors influencing rate and magnitude of bone loss 
following SCI
It has been shown that there are inter-individual and 
site-specific differences in the rate of bone loss after SCI 
(Figure 3), with some individuals approaching published BMD 
fracture thresholds within only 1 year post-injury (around 
67% loss in the distal tibia trabecular BMD) while others 
experience minor BMD reductions within the same period 
(around 1% in distal tibia trabecular BMD)76. Intra-individual 
differences have also been reported in another study where 
bone loss was greater at the proximal tibia compared to the 
distal tibia and more pronounced in the epiphyses than in the 
diaphysis (Figure 2)80, with evidence that inter-site variance 
in bone loss may be related to bone geometry74,80.
An inverse relationship was found between BMD and time 
since injury83,88,95. Unsurprisingly, bone loss has also been 
found to be influenced by the type, level and completeness of 
injury (and resulting function). Lower BMD has been reported 
in the upper extremities55,63,95 and lumbar spine63 in people 
with tetraplegia, compared to those with paraplegia. Patients 
with complete SCI have been found to have significantly lower 
BMD than those with incomplete injuries (BMD= -2.29±0.51 
in complete versus -0.12±0.22 in incomplete, P<0.05)86,95. 
Bone loss has also been found to be influenced by the level 
of injury so that individuals with higher spinal lesions tend to 
have lower BMD (in the affected skeletal sites) compared to 
those with lower lesions56,87,93, but this primarily depends on 
the injury completeness. While it is likely that function linked 
to lesion level affects the extent of bone loss, to date these 
associations have not been reported in the literature.
Neither age78,86 nor sex have been found to have an effect 
on bone parameters after SCI74. However, a significantly 
lower cortical BMD has been reported in females compared 
to males in one study, suggesting a possible effect of 
gender on cortical bone parameters which was proposed to 
be influenced by the postmenopausal females participating 
in this study74. The possible effect of spasticity on BMD 
seems to be unclear with two studies reporting less loss in 
BMD in spastic compared to flaccid patients95,96 and other 
Figure 3. Trabecular BMD of the distal tibia measured in six participants shortly after complete SCI, and 4, 8 and 12 months postinjury76.
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studies reporting no differences in BMD85,87,97,98 between 
the two groups. However, in one of the studies that reported 
a positive effect of spasticity on BMD95, the 41 tested 
participants were a mixture of individuals with paraplegia 
and tetraplegia, and complete and incomplete SCI. It is clear 
that the 2 groups (spastic and flaccid) were not matched for 
these influencing factors.
Fragility fractures after SCI
Osteoporosis is characterised by reduced BMD and 
deterioration in bone micro-structure that consequently 
leads to reduced bone strength and increased susceptibility 
to fracture49. The link to fracture risk has been demonstrated 
as bone geometry parameters73 and BMD were found to be 
lower in participants with SCI who had lower limb fractures 
compared to those with no fracture history6,15,73,87. 
Fragility fractures are common and unresolved 
consequences of SCI57 and are mostly caused by minor 
trauma99 during transfer between surfaces or turns in bed100-
102 or even during rehabilitation training sessions103,104. 
They are more frequent in patients with SCI compared 
to the general population14 and occur predominantly in 
the lower extremities15,57; fewer105 or even no fractures 
have been reported in the upper limbs57,62. The majority of 
these fractures occur in the femur and tibia99 especially at 
epiphyseal sites at the ankle and knee joints57,105. This can 
be linked to the more dramatic and rapid rate of bone loss 
documented in these trabecular bone-rich site compared to 
that in the cortical-rich shaft. 
In general, people with SCI are more likely to sustain 
bone fractures in the chronic phases starting at a mean of 
3 to 8.9 years postinjury15,62,99 (Figure 4). Annual fracture 
rates of individuals with a SCI are double those in uninjured 
(2% and 1% respectively)62 but this additional risk is highly 
site-specific. People with SCI have a 23-fold higher risk of 
experiencing femur fractures whereas upper limb fracture 
risk is lower compared to controls62.
Fractures risk factors
Fractures are more frequent in women and also in men 
with a family or personal history of fractures62,106. Fracture 
risk increases with time since injury99,106, reaching 4.2% per 
year in individuals who sustained an SCI more than 20 years 
ago15. Severity of SCI has also been found to be a contributing 
risk factor, with fractures found to be more common in 
patients with complete SCI than in those with incomplete 
injuries99,105,106. These factors have been shown previously 
to contribute to the magnitude of bone loss following SCI, 
illustrating the correlation between severity of bone loss 
and fracture risk in these patients. Other factors associated 
with high risk of fracture include white ethnicity106 and higher 
alcohol consumption105.
It is worth pointing out that our understanding of many 
Figure 4. Cumulative rate of fracture recorded during the first 10 years postinjury. The black line with triangles represents the rate 
of patients sustaining new fractures while the grey line with circles represents the rate of newly sustained fractures per patient99. 
(Reproduced with permission).
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Table 1. Summary of studies that used ES- interventions to attenuate the loss in BMD after SCI.
Study 
Training 
Modality
Electrical stimulation 
parameters
Produced Stress/
power 
Training dura-tion/
frequency
Injury duration 
and level
Imaging 
modality
Changes in bone 
parameters 
Level of 
evidence
Pacy et al., 
1988130
Leg raising 
against load 
+ bicycle 
ergometer
6s-6s stimulation-rest, 
300µs, 40 Hz. 65-90 V, 
for leg raising against load 
ranging from 1.4-11.4 kg, 
and 80-125 V for bicycle 
ergometry.
From 0 to 18.75 W  
(0-3/8 kilopond)
15 mins, 5 times/week 
for 10 weeks  
(leg raising)  
-15 mins, for 32 weeks 
(bicycle ergometry),  
50 rpm
1, 3 and 4 years, 
T4-T6  
(3 SCI patients) 
N.B.: 1 patient 
had hemangio-
blastoma at T6 for 
6 years
DXA
No change in BMC or 
density
-
Rodgers et al., 
1991128
FNS-induced 
knee extension 
(KE)
Progressive resistance load 
on ankle 0-15 Kg
-
6 KE/min/leg, 3 times/ 
week for 12-18 weeks, 
6.4±6.1 years, 
C4-T10 
QCT No change in BMD Poor
Sloan et al., 
1994123
FES-cycling 
(Also 
participating in 
physiotherapy)
-
50-60 rpm for patients 
with incomplete 
and 30-40 rpm for 
complete SCI
30 min, 3 times/week, 
for 3 months
0.2-11.6 years, 
C5-T12
DXA
No change in BMD  
(BMD tested in only 2 out of 
12 patients)
Poor
Bloomfield 
1996125
FES-cycle 
ergometry
Μonophasic, 350 msec 
duration at 30 Hz and up to 
130 mA
Cycling power up to 
18 W
30 mins, 3 sessions/
week, (80 sessions) for 
9 months
6 years, C5 to T7 DXA
Increased by 0.047±0.010 
g/cm2 at the lumbar spine; 
78% increase in serum 
osteocalcin, PTH increased 
75% but then declined to 
baseline 
Fair
Mohr et al., 
1997114
FES-cycling -
Workload 1/8 Kp- 7/8 
Kp, 18±2 KJ/session 
30 min, 3 days/week, 
for 12 months followed 
by 6 months of 1 
session/ week
12.5±2.7 years, 
C6-Th4
DXA
10% increase in PT BMD. 
This gain faded after 6 
months of reduced training
Fair
Belanger 
2000111
Quadriceps 
contraction 
(resisted & 
unresisted)
300-µsec rectangular pulses 
delivered at 25Hz with a 
5-sec on/5-sec off duty cycle
40 Nm
1-hour a day, 5 days a 
week, for 24 weeks.
9.6±6.6 years, 
C5-T6
DXA
30% of lost BMD recovered 
in distal femur and proximal 
Tibia -Large strength gain
Poor
Eser et al., 
2003113
FES-cycling and 
passive standing 
(2 days/week)
Πeak current =140 mA. 
Pulse width set 0⋅3- 0⋅4 ms, 
frequency set at 30, 50,  
and 60 Hz
Power output between 
0 and 1 kiloponds
30-min, three times a 
week for 6 months
4.5 weeks CT
No effect in tibial cortical 
BMD
Fair
Chen et al., 
2005127
FES-cycling
20 Hz; pulse duration,  
300 µsec; up to 120mA
-
30 minutes/day,  
5 days/week,  
for 6 months
At least 2 years 
and 7 months, 
C5- T8 
DXA
BMD at DF and PT 
increased 11.13%, and 
12.92% respectively, but 
decreased at FN
Fair
Shields et al., 
2006110
ES-isometric 
plantar flexion
10 pulse train (15 Hz, 667ms) 
every 2 seconds
Compressive loads: 
600 N (90% BW) to 
1,107 N (150% BW)
4 bouts/day, each 
consisting of 120 trains, 
5 days/week, for 3 years
4.5 months,  C5 
and T12
DXA
Decline in trained tibial 
BMD (10%) less than the 
untrained (25%)
Fair
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Table 1. (Cont. from previous page).
Study 
Training 
Modality
Electrical stimulation 
parameters
Produced Stress/
power 
Training dura-tion/
frequency
Injury duration 
and level
Imaging 
modality
Changes in bone 
parameters 
Level of 
evidence
Shields and 
Dudley-
Javoroski 
2006122
ES-isometric 
plantar flexion
0-200 mA, 400 V, 10 pulse 
train (15 Hz, 667ms) every 2 
seconds
~1-1.5 times BW
4 bouts/day, each 
consisting of 125 trains, 
5 days/week,  
for ≥2 years
6 weeks, ASIA A pQCT
31% higher distal tibia 
Trabecular BMD compared 
to untrained limb
Fair
Clark et al., 
2007112
ES of quadriceps 
and dorsiflexors
30 Hz, (tetanic) stimulation: 
rest ratio 4:8 s, supine 
position, knee flexed at 20o 
-
15 min sessions, twice 
daily, over a 5-day/week, 
for 5 months
3 weeks,  
C4-T10, (all with 
tetraplegia)
DXA
Different total body BMD at 
3 months only 
Fair
Shields and 
Dudley-
Javoroski 
2007108
ES -isometric 
plantar flexion 
0 to 200 mA at 400 V, 
10-pulse train (15 Hz; 
667ms) every 2s (125 trains 
in each stimulation bout)
Compressive loads 
equivalent to 110% of 
body weight
30 min/day, 5 days a 
week, for 6-11 months
>2 years ASIA A DXA
No change in proximal tibia 
BMD
Fair
Frotzler et al., 
2008115
FES-cycling
50 Hz, pulse width = up to 
500 µs, current amplitude = 
80-150 mA 
-
58±5 min, 3.7±0.6 
sessions/week for  
12 months
11.0±7.1 years pQCT
Increases in distal femoral 
epiphysis BMD are: 
14.4±21.1% in trabuclar 
BMD, 7.0±10.8% in total 
BMD and 1.2±1.5% in CSA
Fair
Griffin et al., 
2009119
FES-cycling
50 HZ, up to 140 mA,  
49 rpm
0.71-10.51 W
30 min, 2-3 times/week 
for 10 weeks
11±3.1 years, 
C4-T7
DXA No difference in bone mass Poor
Lai et al., 
2010117
FES-cycling
20 Hz; 300 µsec, 
(electrodesat mid quads and 
hamstirngs)
 -
30 min, mean of 2.4 
sessions/week, for 3 
months
26-52 days, 
C5-T9 
DXA
Decreased rate in distal 
femur BMD less in trained 
group (2.23% in trained; 
6.65% in controls)
Fair
Dudley-
Javoroski et al., 
2012109
Compressive 
loads applied 
during stance by 
quadriceps ES
60, 100-pulse trains (20 Hz, 
200 µs, up to 200 mA), each 
train followed by 5 s rest
150% body weight 
(BW)
30 mins, 5 days a week 
for 3 years 
0.19- 24.23 
years, C5-T12
pQCT 
BMD in limbs that received 
40% BW and untrained 
was 61.1% of that of 150% 
BW limbs
Poor
Gibbons et al., 
2014129
FES-rowing  
(1 participant)
50 µsec pulse width, 50 Hz, 
up to 115 mA unramped 
stimulation.
-
30-45 mins, For > 8 
years
13.5 years, T4 pQCT
PT trabecular BMD was 
higher in trained participant 
compared to SCI group but 
less than able-bodied.
Single 
case 
study
Gibbons et al., 
2016116
FES-rowing
Lower limbs exposed to 
~2700 loading cycles/week
-
3 times/week, 30-min 
rows at 30 strokes/min, 
13.5 years, T4 HR-pQCT
Majority of tibial trabecular 
and cortical measurements 
were within ~1 s.d. but 
strength was lower.
Single 
case 
study
Johnston et al., 
2016131
FES-cycling 
(compare 
low and high 
cadences)
250 µs, 33 Hz,  
and up to 140 mA
Low: 20 rpm, 
2.9±2.8Nm,  
High: 50 rpm,  
0.8±0.2 Nm
56 min, 3 times/week 
for 6 months
1-27.5 years, 
C4-T6
DXA and MRI 
(micro- 
structure)
Greater decreases in 
alkaline phosphate and 
N-telopeptide in low 
cadence
Fair
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aspects of fragility fractures after SCI such as risk factors and 
fracture thresholds, is limited by the few studies addressing 
these issues. More studies should be carried out to obtain 
clarity which should result in the development of effective 
interventions. 
Complications of fractures
About 50% of fractures in individuals with SCI are 
associated with clinical complications99,105 such as infections, 
pressure ulcers101,105, delayed healing, autonomic dysreflexia, 
increased muscle spasticity and depression105,107. Delayed 
union can lead to further surgical interventions and therefore 
prolonged hospitalisation and increased cost57. 
Effective interventions that target bone health and 
attenuate the rapid decline in bone microstructure and 
geometry should be incorporated into the patient’s treatment 
plan as soon as they are clinically stable. However, there is 
currently no evidence that supports the effectiveness of any 
intervention in preventing fragility fractures. 
Therapeutic Interventions targeting bone loss 
after SCI
Different physical and pharmacological interventions have 
been tested in patients to investigate their effectiveness in 
reversing or attenuating bone loss in the acute and chronic 
phases, respectively.
Interventions based on electrical stimulation (ES)
Different ES-induced interventions have been employed 
to improve muscle and bone health and attenuate their 
deterioration after SCI by eliciting muscle contractions 
and thereby restoring bone loading. Functional electrical 
stimulation (FES) techniques applied to the paralysed limbs 
of people with SCI use surface electrodes to either activate 
one muscle group to produce joint extension or flexion108-112, 
or induce co-ordinated contractions of two or more muscle 
groups to produce functional movements such as cycling 
and rowing113-117. While pronounced improvements in body 
composition118,119 muscle geometry114,115,120,121 and functional 
properties108,111,121-123 have been widely documented, the 
evidence for the efficacy of FES interventions in attenuating 
bone loss is equivocal. 
Significant site-specific improvements in BMD (ranging 
between 7-30% increase in BMD) have been reported in some 
of these studies109-111,115-117 as shown in Figure 5. In contrast, 
others found no effect on BMD after undergoing 5-12 months 
of electrical stimulation-induced training108,112,113. Table 1 
provides a summary of all studies that used ES- interventions 
to attenuate the loss in BMD after SCI.
This discrepancy in the documented results of FES on bone 
health might be due to different factors related to the patient 
population, intervention protocols and the imaging modalities 
used to assess changes in bone124. For example, a patient’s 
postinjury duration and level of injury seem to influence 
intervention effectiveness considerably. Studies showed that 
starting FES interventions within the first few weeks (1-7 
weeks) after SCI was effective in attenuating BMD decline in 
trabecular-rich regions of the femur and tibia117,122 but with 
no effect on cortical BMD113. Individuals with paraplegia seem 
to achieve greater FES-cycling power when compared with 
people with tetraplegia (22.5 W and 4.8 W, respectively)125. 
This is likely due to the preserved control of their upper body 
which enables them to better coordinate movement with the 
pedalling action of the lower limbs and thereby delay fatigue 
in the leg muscles.
The magnitude of the elicited muscle forces and 
the session duration and frequency also influence the 
intervention results. This is probably because they determine 
the magnitude of the mechanical loads acting on bone which 
need to be large enough to exceed the remodelling threshold 
and induce bone formation126. BMD has been reported to be 
significantly greater in patients who trained at higher cycling 
power (≥18 W)125 or received larger compressive loads 
(150% body weight)109, compared to that measured at the 
same sites in patients who trained at lower cycling power 
(≤12 W) and compressive loads (40% BW), respectively. 
Training paralysed muscles for at least 1 hour per day111,115, 
Figure 5. Changes in BMD at distal femur, proximal tibia and mid 
tibia (as absolute values in A and as percentages of uninjured 
controls values in B) after undergoing 6 months of ES-knee 
extension intervention111. (Reproduced with permission).
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for 5 days per week109-111,127 seems to be more effective in 
attenuating BMD loss compared to a training protocol of 30 
min, or 3 days per week113,119,123,128. Furthermore, significant 
improvements have been shown from training interventions 
that have lasted at least 6 months109-111,114,115,122,125,127,129 
compared to those lasting less than 6 months and reported 
no change in bone mass119,123,128,130. This suggests that bone’s 
response to such interventions is highly dose-dependent. 
The magnitude of muscle forces elicited by ES has not been 
reported in many of these studies112,115-117,127-129. However, 
some studies measured indirect indicators of muscle force 
such as joint torques (40 Nm111 and up to 3 Nm131) and applied 
loads as percentages of body weight108-110,122 (110%, 150%, 
90-150% and 100-150% BW, respectively). These achieved 
loads are comparable to the compressive forces applied on 
the knees of uninjured individuals during daily activities such 
as stair descending (123.58% BW) and walking (101.03% 
BW)132. It has also been suggested that a minimum knee 
extensor torque of 50 Nm is required to achieve standing 
and walking using FES111 and at least 35.3-49.2 N/kg muscle 
force of the knee and hip extensors is required to achieve a 
sit-to-stand movement133.
Other studies reported the achieved cycling cadences123,131 
(ranging between 20-60 rpm) and power119,125,130 (10-18.75 
W) as an outcome measure. However, these are not accurate 
indicators of muscle force and thereby bone loading, 
because of the inverse relationship between force/load and 
contraction velocity in skeletal muscles. This concept is 
demonstrated by considering that high cycling power can be 
achieved by exerting low force at higher speed as well as by 
high force and lower speed109,110. It is the latter form of high-
power cycling (high force, combined with a low velocity) that 
has been shown to improve bone parameters most effectively 
in people with SCI131.
These different ways of measuring the outcome of the 
aforementioned interventions do not lend themselves well 
to quantitative comparisons, in terms of the muscle forces 
produced. Nevertheless, a qualitative comparison between 
different training approaches (cycling, rowing and resistance 
training) can be made. Whereas cycling requires stimulating 
the quadriceps, hamstrings, gluteal muscles and (in some 
studies) calf muscles, most of the resistance training studies 
targeted one muscle group such as the quadriceps109,111 or 
the soleus110. Stimulating one muscle group has been found 
to mitigate the loss in BMD asymmetrically, on one side/half 
(posterior) of the lower limb long bones134,135. Accordingly, 
it might be speculated that stimulating the antagonist 
muscle pairs could have a more homogenous effect on BMD 
throughout the different areas of the bone. 
The imaging modalities used to evaluate the effectiveness 
of FES interventions are another important methodological 
consideration. DXA does not distinguish between trabecular 
and cortical bone and thereby is not able to detect early 
potential changes in response to training, which are known 
to occur more rapidly in trabecular than in the cortical 
compartments115. This is illustrated in Figure 6, which shows 
the effect of training on femur trabecular bone using CT20, 
with no apparent differences in the cortical shell. Moreover, 
DXA does not typically provide site-specific scans for regions 
such as distal femur and proximal tibia which are of clinical 
interest and are likely to be stressed by cycling exercise.
Only one study estimated the effect of ES-training on bone 
strength116, reporting increases in multiple trabecular and 
cortical parameters after ES-rowing intervention. However, 
bone strength (which was estimated using computational 
modelling from biomechanical indices such as stiffness (-3 
SD) and predicted failure load (-3.5 SD)) was lower than non-
SCI controls; this was proposed to be related to the larger 
percentage cortical porosity (+4.6 SD) and mean pore 
diameter (+3.7 SD)116. More studies are required to investigate 
the effect of ES-interventions on bone strength alongside 
structural and geometric parameters (as no effect was found 
in the latter in one study114) to assess their effectiveness in 
preventing fragility fractures.
Different forms of ES-interventions seem to partially 
reverse BMD when applied intensively over the long-term 
in people with chronic SCI. However, these improvements 
have not been shown to lead to fracture risk reduction (which 
would be considered the desired and clinically relevant 
outcome). The biomechanical loads/forces elicited by these 
interventions should be measured and further tested to find 
out how could they be delivered effectively and safely. Ideally, 
Figure 6. Upper panel: CT images of an untrained (left) and 
trained (right) limbs at 12% of the femur length. Lower panel: 
3D reconstruction of the trabecular lattice at the same region 
showing the greater loss in the untrained compared to the trained 
limb109. (Reproduced with permission).
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the ES-interventions would mimic the voluntary muscle 
loading exerted by able-bodied individuals during daily 
activities. Additional research is also needed to determine 
whether it is possible to identify a ‘loading dose threshold’ 
above which fracture risk could be significantly minimised.
Other physical interventions
Weight bearing
Other forms of physical training interventions include 
weight-bearing activities such as standing and walking, which 
aim to load the lower limb bones through axial compression, 
bending and torsional stresses that would normally act on 
the lower extremities during standing and ambulation. 
Most of the reviewed studies (11 out of 16 studies) based 
on conventional standing training (using standing frames, 
wheelchairs and leg braces)64,87,136-139, exoskeletons140-143 or 
treadmill walking144,145 did not show improvements in BMD, 
either during the acute phase137,139,144 or during the chronic 
phase64,87,136,138,140,141,145. Only four studies showed positive 
results in bone parameters by preventing bone loss in the 
acute to sub-acute phase (standing and treadmill walking)146 
and increasing BMD in the chronic phase (treadmill training)147 
(passive standing)148,149. The participants recruited were 
full-time wheelchair users with complete SCI in some of 
these studies136,139-142,148,149, or had incomplete injuries (or a 
mixture of both) in other studies64,87,137,138,144-147. Only three 
studies reported that the recruited participants were already 
physically active before their recruitment144,147,149. Two of 
these studies reported a positive impact of the intervention 
on BMD147,149, which suggests that being active might 
have improved their muscle health and attenuated their 
atrophy which in turn optimised their force production and 
subsequently their impact on bone stimulation.
These improvements range from 7-9% larger BMD at 
different sites in the lower limbs in standing groups compared 
to controls. However, one of these studies was a single 
case study recruiting a subject with motor-incomplete SCI 
(achieving a 20% increase in tibial trabecular BMD)147, which 
in itself is known to lead to less bone loss than complete 
SCI86,95. Goemaere et al reported an improvement in femoral 
shaft BMD but not in the proximal femur149. These results 
were explained by a possible difference between cortical and 
trabecular bone in the minimal effective strain for initiating 
bone remodelling (being reached more rapidly in cortical 
bone)149, although recent evidence suggests that there 
are regional variations (regardless of bone type) in strain 
thresholds within the same bone150. In this study, however, 
the effect of standing was not investigated at the sites that 
are known to be most prone to fragility fractures in people 
with SCI (distal femur, proximal tibia and distal tibia). The 
last study reported attenuation of bone loss based on bone 
formation and resorption biomarkers but BMD results did not 
always match the biomarker results151.
To summarise, to achieve significant improvements in 
BMD in the lower limbs from standing and walking, long-term 
training sessions should start within the first few weeks after 
the injury onset146,148. Combining ES with weight bearing 
activities may have a greater positive effect on bone than 
performing these activities on their own147. While the duration 
of the ES-training has been shown to have an impact on 
BMD152, standing for different durations (<1 hour, 1 hour and 
>1 hour)64,138 and frequencies (daily standing versus standing 
for 3 times/week)149 seems to have no significant effect on 
BMD. This might indicate that the compression stresses 
produced during standing alone are insufficient to stimulate 
lower limb bones even when applied for longer durations.
Similarly, bone stresses delivered through treadmill 
walking seem to be insufficient to induce adequate bone 
stimulation. This is, likely because of partial bodyweight 
support and low treadmill speeds used compared to normal 
walking speed144, which would result in lower bone strains153. 
It should also be noted that the atrophied muscles of patients 
with SCI would produce smaller bone strains when contracting 
which would make them less effective in inducing osteogenic 
effects in the bones of the paralysed limbs142. Again, as seen 
with FES interventions, the dosage of the mechanical loading 
acting on bone that is required to attenuate or reverse bone 
loss effectively is yet to be ascertained154. 
Additional studies are also needed to determine whether 
partial body-weight supported treadmill training and other 
gait rehabilitation orthoses are more effective in terms of 
bone stimulation than conventional training144 and whether 
they could be used safely for long term intervention, as 
home-based rehabilitation devices141.
Ultrasound
As high-frequency mechanical waves, ultrasound was 
thought to be a potential technique to stimulate bones 
with mechanical signals. This concept is based on results 
of a number of in-vitro trials where low-intensity pulsed 
ultrasound has been reported to induce osteogenic 
responses155,156. However, in the published literature there 
is only one study that investigated its effect on bone health 
in people with SCI. The study found no significant effect of 
applying pulsed ultrasound for 6 weeks on calcaneal bone 
loss157, although the short trial duration likely limited the 
relevance of the study. Further investigation should be carried 
out to study the effects of varying ultrasound parameters, 
as well as, the intervention duration and frequency on its 
effectiveness in treating bone loss after SCI.
Whole Body Vibration
Whole body Vibration systems have been used in people 
with SCI to deliver vertical or side-alternating oscillations 
throughout the long bones using a vibrating plate upon which 
the feet are situated, either while the participant is sitting158 
or passively standing159. In the former, the limb is fixed using 
external compressive loads (35% BW) in order to optimise 
the transmission and effectiveness of the vibrations158. It has 
been reported that neither 6 months159 nor 12 months158 
of applying whole body vibration combined with weight-
bearing activities has induced any improvements in BMD 
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Table 2. Summary of studies that used other physical interventions (without electrical stimulation) to attenuate the loss in BMD after SCI.
Study Training modality Produced Stress/power 
Training duration/
frequency
Injury duration 
and level
Imaging modality Changes in bone parameters 
Level of 
evidence
Biering-
Sørensen et al., 
198887
Standing or walking using 
long leg braces
 - For at least 1 hour daily
2-25 years, 
C7-L3 
DXA No effect on BMC -
Kunkel et al., 
1993136
Standing in frame  -
45 min/twice daily for 5 
months (144 h over 135 
days)
10-39 years, 
C6-T12,  
(4 SCI, 2 multiple 
sclerosis 
patients)
DXA No change in BMD Fair
Goemaere et 
al., 1994149
Passive Standing using:  
1. long leg braces,  
2. standing frames,  
3. standing wheelchairs)
-
Daily standing for 1 hour in 
1 group and 3 times/week in 
the second group
12-118 months. 
Complete 
paraplegia
DXA
BMD better at femoral shaft but 
not proximal femur compared to 
non-standing
Fair
Thoumie et al., 
1995141
Gait rehabilitation with 
hybrid orthosis
-
2 hours, 3 times/week,  
for 16 months
15-60 months, 
T2-T10
DXA
Significant decrease in BMD at 
femoral neck and no change at 
lumbar spine
Poor
Needham-
Shropshire et 
al., 1997142,143
Standing and walking using 
a device that combined ES 
and a modified walker
 -
3 times/week, 12-20 weeks, 
(mean of 143.6±86.4 mins 
persession)
At least 6 
months,  
T4-T11
DXA
No significant change in BMD at 
FN, neck, and Ward’s triangle
Fair
de Bruin et al., 
1999146
Standing and treadmill 
walking
Treadmill speed= 
1.3 km/h
30min standing,  
30 min walking, 5 days/week 
for 6 months
1-4 weeks, 
C4-L1
pQCT
Almost no loss in tibia trabecular 
BMD in trained group compared 
to -6.9% to -9.4% loss in 
trabecular bone
Fair
Dauty et al., 
200064
Passive standing -
Daily for: 1. less than 1 h,  
2. 1 h,  
3. More than 1h
68.3±74.7 
months
DXA No effect on BMC -
Frey-Rindova 
et al., 2000137
Standing using frame (for 
complete SCI) and treadmill 
walking (for incomplete SCI)
 -
At least 30min, 3 times/
week for 2 and half years 
(treadmill speed 1.3 km/h)
1-4 weeks pQCT No effect on BMD -
Warden et al., 
2001157
Pulsed US -
20 min, 5 days/week for 6 
weeks US settings: 10 µsec 
1.0 MHz sine waves, 3.3 kHz
1-6 months, 
C5-T10 
DXA
No effect on calcaneal bone 
parameters
Fair
Ben et al., 
2005139
Standing on 1 leg  
(on tilt table)
17 Nm dorsiflextion 
torque
30 min, 3 times/week,  
for 12 weeks
4±2 months DXA Little or no effect on femur BMD Good
Giangregorio et 
al., 2005144
Body weight supported 
treadmill 
-
Less than 1hour, 2 times/
week (48 sessions in 8 
months) (speed= 0.7-2 km/h)
2-6 months, 
C3-C8
DXA and CT
No effect on BMD (proximal and 
distal femur, PT, spine) or CSA 
(mid-femur, PT)
Poor
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Table 2. (Cont. from previous page).
Study Training modality Produced Stress/power 
Training duration/
frequency
Injury duration 
and level
Imaging modality Changes in bone parameters 
Level of 
evidence
Carvalho et al., 
2006151
Treadmill gait training 30-50% BW supported
20 min, 2 times/week  
for 6 months 
25-180 months, 
C4-C8
DXA
Most of the participants showed 
increased bone formation and 
decreased bone resorption  
(BMD results did not always 
match biomarkers results)
Poor
Giangregorio et 
al., 2006145
Body weight supported 
treadmill
-
3 times/week, For 12 months 
(144 sessions)
1-24 years (all 
Incomplete)
DXA and CT
No effect on BMD (at proximal 
and distal femur, PT, spine) or 
CSA (mid-femur, PT)
Poor
Alekna et al., 
2008148
Passive standing in frame  -
For at least 1 hour/day,  
no less than 5 days/week 
8-12 weeks, 
C2-L1 
DXA
Higher BMD in lower limbs after 
2 years in standing group  
(1.018 compared to 0.91 g/cm2)
Fair
Goktepe et al., 
2008138
Any form of Standing:  
1. More than 1hour,  
2. Less than 1hour,  
3. No standing
- Daily standing
At least 1 year, 
ASIA A, B 
DXA
No significant difference between 
groups in BMD at PT  
and lumbar spine
Fair
Coupaud et al., 
2009147
Partial body-weight 
supported treadmill training 
(BWSTT) + FES on one side 
(bisphosphonate + Vitamin 
D prescribed independently)
30% BW support -Speed 
increased from  
0.1 m/s to 0.3 m/s
Muscle conditioning over 2 
months Target increased for 
15 min to 30 min,  
3 time/week for 5 months.  
FES: 40Hz, 40mA,  
and 117-351µs
14.5 years, T6 
(incomplete)  
(one subject)
pQCT
Increase of 5% (right) and 20% 
(left) in DT trabecular BMD. 
Changes are negligible in PT  
and DF
Single case 
study
Davis et al., 
2010160
3 phases of training:  
1. standing only,  
2. partial standing/WBV 
(foot only on plate),  
3. standing with vibration
-
1. Phase 1:  
40 min, 3 times/week, for 10 
weeks,  
2. Phase2: 20/20 mins, 3 
times/week,  
3. Phase3: 7 mins/session, 3 
times/week
4 years, T10 
(incomplete), 
(single case)
DXA
Improvement in BMD in the trunk 
and spine after phase 3 only.  
No effect on legs
Single case 
study
Wuermser et 
al., 2015159
Low-magnitude whole body 
Vibration+ passive standing
About 76-86% BW
20 mins, 5 days/week,  
for 6 months  
(0.3 g, 34 Hz,50 µm.)
2-27 years,  
T3-T12 
DXA and  
HR-pQCT
No effect on BMD at PF or 
microstructure at DT
Fair
Dudley-
Javoroski et 
al., 2016158
Body Vibration
35% BW applied during 
the vibration training
3 times/week, for 12 months 
Vibration parameters:  
0.6g, 30 Hz, 20 min,  
three times weekly)
0.1 to 29.2 
years, C7-T4 
pQCT
No effect on trabecular 
microstructure or BMD at DT 
and DF
Fair
Karelis et al., 
2017140
Walking with a robotic 
exoskeleton
 -
Up to 60 min, 3 times/week 
for 6 weeks Mean standing 
time/session: 48.4 min, 
walking time: 27.0 min
7.6 ± 4.6 years, 
C7-T10 
DXA No significant change in BMD Fair
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or microstructure of the lower extremities. Only one study 
reported an improvement from whole body vibration (when 
combined with standing) in BMD (using DXA) in the spine 
(8.3%) and trunk (5.5%), but not in the lower extremities160. 
Whole body vibration has been incorporated into the 
rehabilitation programmes of some patients with SCI very 
recently, but the number of studies that have investigated 
its effect on bone health is very limited. A summary of 
the studies that investigated the effect of weight bearing 
exercises, ultrasound and whole-body vibration on BMD after 
SCI, can be found in Table 2.
To summarise, most of the physical interventions had 
limited effects on bone health. This may be related to an 
inability of current methods to develop or safely apply large 
internal muscle forces or external forces to bone. For those 
with chronic SCI, treatments aimed at reversing osteoporosis 
should be considered, but are less likely to be effective in 
restoring BMD values to within the normal range152. This 
has been proposed to be due to the weaker bone losing its 
ability to adapt to applied strains108 which might be due to 
the cellular accommodation phenomenon161 or osteocyte 
apoptosis162. Moreover, patellar tendon stiffness was found to 
be reduced by up to 77% in people with chronic SCI compared 
to uninjured controls163. This would make force transmission 
from muscles to bones through tendons more difficult and 
less efficient163.
Pharmacological interventions (Bisphosphonates)
A wide range of pharmacological treatments for 
osteoporosis are currently available, such as strontium 
ranelate164, denosumab165, selective oestrogen receptor 
modulator drugs166 and bisphosphonates. The latter are the 
most commonly prescribed treatments for osteoporosis 
in women167-169 and men170,171, and have been found to be 
effective in attenuating bone resorption, restoring BMD and 
preventing fractures172. 
Bisphosphonates are anti-resorptive agents that reduce 
the bone resorption rate by targeting osteoclasts, inhibiting 
their activity and subsequently reducing their number in the 
long term173. They are administered either orally on a daily or 
weekly basis174 or as an annual single67,175 or multiple (every 
month or 3 months)176,177 intravenous injection. Patients 
taking bisphosphonates on a weekly basis have been found 
to be more compliant and to persist with the treatment 
compared to those who take a daily dose174. 
However, bisphosphonates studies conducted in patients 
with acute SCI showed mixed results, with 5 out of 9 
studies reporting positive effects. Alendronate (weekly for 
12 months) has been found to preserve total body and leg 
BMD178. Intravenous bisphosphonates such as zoledronate 
and pamidronate have been shown to have positive effects 
on BMD in the lower limbs177, hip and spine67,179. One study 
reported little effect of disodium dichloromethylene 
diphosphonate on BMD at the distal tibia180. 
These agents resulted in a lower limb BMD that was 7-17% 
higher compared to untreated controls. However, it should be 
pointed out here that in three of these studies, about one third 
of the participants were classified as having an incomplete SCI 
(with good preservation of motor function) and were not full 
time wheelchair users177-179. With only two studies reporting 
positive results in participants with complete SCI67,180: one 
reported only a marginal effect on BMC at the distal tibia 
(7%)180 while the other reported about 12% greater BMD at 
the hip67. The reduction in bone loss in the acute phase after 
pamidronate and zoledronate administration (administered 
once a year) has been reported in some studies to be 
temporary, lasting 6 months (after the annually administered 
dose)175 although the treatment was not discontinued in one 
study176. This might indicate that the dose or the frequency of 
administration could be further investigated to prolong their 
effect. Another study reported no effect of the treatment at 
the knee which might suggest that such treatment is effective 
in attenuating cortical but not trabecular bone loss173.
Based on the results reported in these studies, there is 
little current evidence that supports the effectiveness of 
bisphosphonates in attenuating/preventing bone loss in 
the acute phase of complete SCI at the lower extremities. 
It was apparent that most studies did not investigate the 
effect of these treatments in the sites that are most prone 
to fracture, in part because these sites were only identified 
relatively recently. However, a number of these studies have 
been carried out since the fracture-prone sites after SCI 
were identified and published15,55,181 and so, this is unlikely to 
explain all the lack of relevant evidence for the effectiveness 
of pharmacological intervention to treat bone loss after SCI. 
Furthermore, these findings are possibly due (in part) to the 
measurement technique used and the lack of studies that 
investigated these sites using a 3D imaging technique (e.g. 
pQCT). Positive changes might have been achieved in the 
trabecular bone (which responds to interventions faster 
than cortical bone), but it was not possible to observe it with 
DXA imaging.
Fewer studies investigated the use of bisphosphonates 
in the chronic phase of SCI173,182,183 and one study included 
a mixed patient group with acute and chronic SCI184. The 
effects of alendronate on leg BMD seem to be influenced 
by treatment duration. A daily dosage of alendronate 
administered orally had no effect on lower limb BMD171 
over 6 months, but it attenuated bone loss by 9%184 when 
administered for 2 years. 
As one of the only two studies that reported significant 
effects of bisphosphonates in the chronic phase, was a 
single case study of a patient with incomplete SCI182, it can 
be concluded that there is no sufficient data to assess their 
effectiveness for osteoporosis in chronic SCI. It is clear that 
the positive effect of bisphosphonates on BMD in the chronic 
phase of SCI is limited when used as the only intervention. 
Furthermore, and crucially, it does not exceed keeping BMD 
within its current level without restoring what has been lost, 
which could be less effective in the chronic phase (after 
reaching steady state) compared to the acute phase 
A number of issues can be highlighted after reviewing 
the use of bisphosphonates in people with SCI. Firstly, 
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Table 3. Summary of studies that used pharmacological treatments to attenuate the loss in BMD after SCI.
Study Treatment Injury duration and level Dose, Duration & frequency Imaging device Changes in BMD Supplements
Level of 
evidence
Minaire et al., 
1981180
disodium 
dichloromethylene 
diphosphonate
Acute SCI, T1-T12, 
(all with complete 
paraplegia)
400 or 1600 mg/day  
for 3.5 months
Photon 
absorptiometry
Little effect in BMC at distal tibia  
(for 400 mg) - Fair
Pearson et al., 
1997187 Cyclical Etidronate
Within 6 weeks, 
C5-T12
Orally 800mg/day  
for 2 weeks, this was 
repeated after 13 weeks 
DXA BMD maintained only in ambulatory treated patients - Poor
Nance et al., 
1999177
Intravenous 
Pamidronate 6 weeks, C4-T12 
30-mg infusion/month  
for 6 months DXA
Greater BMD at hip, femoral and tibial 
diaphyses, femoral and tibial epiphyses 
(less bone loss in ambulatory)
Calcium: 1000 mg daily Poor
Sniger and 
Garshick, 
2002182
Alendronate 
27 years,  
C4 (incomplete), 
(single case)
Daily: 1. Alendronate: 10mg, 
2. Vitamin D: 400mg,  
3. Calcium carbonate 
500mg, daily for 2 years
DXA Increased BMD at spine and lower legs
Vitamin D: 400 mg/d Calcium 
carbonate:  
500 mg/d
Single case 
study
Zehnder et al., 
2004184 Alendronate 
0.1-29.5 years,  
T1-L3, (all with 
complete SCI)
10mg + 500 mg calcium 
daily for 24 months DXA
BMD at distal tibia, tibial diaphysis and 
total hip remained stable compared to 
control group
Elemental calcium: 500g/d Fair
Bauman et al., 
2005176
Intravenous 
Pamidronate
22 to 65 days,  
ASIA A, Acute SCI
60 mg given at 1, 2, 3, 6, 9, 
12 months DXA
No changes in long term  
(12, 18,24 months) although reported 
early (1,3,6 months) reduction in bone 
loss in total leg BMD
Calcium:  
at least 700 mg/d in diet Fair
de Brito et al., 
2005173 Alendronate 
13.1-255.7 months, 
ASIA A, B, C
10 mg (+1000 mg Calcium), 
daily for 6 months DXA General increase in BMD Calcium: 1000 mg/d Fair
Mechanick et 
al., 2006186
Intravenous 
Pamidronate
Acute SCI,  
AIS A, B, C
90 mg over 4 hours  
(single dose) -
Reduced bone resorption biomarkers, 
BMD not tested
-Calcium: 1,000 mg daily, 
-Calcitriol: 0.25 µg daily -
Gilchrist et al., 
2007178 Alendronate
Within 10 days, 
C4-L2
70 mg once weekly,  
for 12 months DXA
Total and hip BMD was 5.3% and 
17% greater in intervention group 
respectively. Effects sustained for more 
6 months after treatment discontinued
- Fair
Shapiro et al., 
2007175
Intravenous 
Zoledronate
10-12 weeks,  
C2 to T12
4 or 5 mg (administered 
once) DXA
BMD and CSA increased at proximal 
femur only at 6 months, and for 12 
months at the femoral shaft
Calcium: 800 mg,  
Vitamin D: 800 IU  
(both from diet)
Fair
Bubbear et al., 
2011179
Intravenous 
Zoledronate
Within 3 months, 
C4-L3 4 mg (administered once) DXA
Higher BMD at total hip (12.4%) 
trochanter (13.4%), and lumbar spine 
(2.7%) up to 12 months 
- Fair
Bauman et al., 
201567
Intravenous 
Zoledronate
Within 3 months 
ASI A, B (all with 
compete SCI)
5 mg (administered once) DXA Reduction of BMD loss at the hip but not at the knee
Calcium carbonate:  
1250 mg/d  
Vitamin D: only for participants 
with levels <20 ng/ml
Poor
Haider et al., 
2019185
Teriparatide (in 
previous study) 
followed by oral 
alendronate
15±9 years, ASI A, 
B, C (C1-L5)
Teriparatide: 12-24 months 
Alendronate: 70 mg once 
weekly for 12 months
DXA
Significant increase in aBMD at the spine 
2.5% and in BMC at femoral epiphysis, 
metaphysis, and diaphysis, 15%, 7.7%, 
3.0%, respectively.  
- no clear results at the tibia
Vitamin D (cholecalcifer-
ol 1000 IU) daily -calcium 
carbonate: 1000 mg daily
Fair
Gifre et al., 
2016191 Denosumab
15±4 months, C4-T8 
(ASIA 12A, 1B, 1C)
60 mg every 6 months for 
up to 12 months DXA
Increases in lumbar (8%) and femoral 
BMD (3%) Calcium and Vitamin D Fair
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most of these studies tested these treatments in 
patients with different ambulatory capabilities and injury 
severity173,177-179,185-187. Some of these studies showed more 
pronounced improvements in ambulatory compared to 
non-ambulatory participants177,187. Despite the fact that 
there appear to be comparable numbers of studies with 
mixed and complete SCI that reported positive results of 
pharmacological interventions (4 studies with mixed group 
(complete and incomplete SCI) and 3 studies of complete SCI 
only), testing these agents on only non-ambulatory patients 
with complete SCI would give a clearer indication of their 
effectiveness in restoring BMD and preventing fractures67,188. 
As a minimum, where mixed patient groups are used, 
completeness of injury should be included in the data analysis 
and reporting of findings. 
Secondly, very few studies investigated the effect of these 
treatments on BMD at the sites that are most susceptible to 
fracture in people with SCI67,180,184, such as the distal femur 
and proximal and distal tibia57. Furthermore, the use of pQCT 
(instead of DXA) could provide more quantitative insights 
into whether cortical bone and trabecular bone respond to 
such agents to similar or different extents.
Although these studies reported no173,178 or only acute 
mild side effects179,186, osteonecrosis of the jaws189 and 
spontaneous fractures190 are considered as rare side effects 
of using oral bisphosphonates in osteoporotic patients. Other 
clinical treatments have therefore been suggested to be tested 
on people with SCI such as the anti-resorptive denosumab 
and anabolic therapies such as sclerostin antibodies67. Gifre 
et al reported an increase in lumbar and femoral BMD (8% 
and 3% BMD respectively) after administering Denosumab 
in people with acute SCI for 12 months191. This was the 
only study testing Denosumab in people with SCI. Table 3 
provides a summary of all studies that used pharmacological 
treatments to attenuate the loss in BMD after SCI. 
Combination treatment interventions
Despite the reported mitigated bone resorption in the 
acute phase67,177,178 and the stabilised BMD in the chronic 
phase183,184 in many of these studies , no increase in BMD has 
been reported, indicating a need for an intervention with an 
anabolic effect that can be combined (or used sequentially) 
with anti-resorptive agents to boost their effect183,192. The 
additive effect of anti-resorptive medications combined 
with the anabolic stimulus of physical activity may explain 
results from a number of bisphosphonate studies reporting 
more pronounced improvements in BMD in ambulatory 
individuals than in full time wheelchair users177,187. 
Furthermore, combining exercises with anti-resorptive 
therapies has been reported to have a greater effect on 
BMD compared to using antiresorptives alone in different 
models of osteoporosis193,194 but the number of studies 
examining such approaches is small195.
Remembering the significant role of mechanical stresses in 
preserving/losing BMD might suggest that bisphosphonates 
should be accompanied by physical training in order to achieve 
optimum benefits in people with SCI196. Hypothetically, by 
combining these interventions, the anti-resorptive agent 
would target the inhibition of osteoclastic activity, while the 
skeletal loading could have a role in simulating osteoblasts, 
thus mitigating the imbalance between bone formation and 
resorption caused by the SCI. In a recent study, significant 
increases in geometric cortical bone parameters (cortical 
bone volume, cortical thickness index, and buckling ratio) 
were reported at the distal femur and proximal tibia in 
the group that had FES-rowing training combined with 
zoledronate administration compared to the group that 
performed FES-rowing alone197. This is clinically-relevant as 
reductions in these geometric cortical bone parameters after 
SCI are thought to be associated with osteoporotic fractures 
in this patient group197.
The anabolic parathyroid hormone teriparatide has been 
also investigated in combination with gait training192, with 
vibration198 and following 12 months of bisphosphonates 
treatment185. The first study reported no effect on BMD (i.e. 
with gait training)192. The second study reported that the 
combination of vibration with teriparatide did not augment 
its effect on BMD198, while in the latter(involving combination 
with bisphosphonates), an increase in BMC ranging between 
3-15% was reported in different parts of the femur185. Studies 
that tested these combined treatments in people with SCI are 
summarised in Table 4.
Levels of evidence
After reviewing all available interventions aiming to 
mitigate bone loss in people with SCI, the quality of these 
studies was assessed. Only studies that investigated BMD 
as their primary outcome were included in this assessment, 
due to the well-documented link between BMD and fracture 
incidence in people with SCI6,15. Furthermore, it is the most 
commonly measured bone parameter among all studies in 
the SCI population.
The levels of evidence were assessed following the 
approach described by Bryson et al., 2009188 which was based 
on the Delphi list 9 items. Each of these items (listed in Tables 
5,6,7 (provided in Online Resource 1)) was given a subscore 
of either 1 (not reported), 2 (fair) or 3 (good), except for the 
randomisation item which was given a score of 0 (if the study 
was not randomised). Items 5,6,7 were all merged together 
under one category due to the small numbers of studies 
that reported blinding of the patient (which was difficult to 
achieve especially for physical interventions), assessor or 
the caregiver. All subscores were summed to determine the 
overall quality rating (poor, fair, good).
All the reviewed studies were either of a poor or fair quality 
except one study that tested the effect of standing and was 
of a good quality139. For both the ES and the pharmacological 
interventions studies, 30% were of poor quality while about 
70% were of fair quality. Other physical interventions (such 
as weight bearing) studies showed comparable levels of 
evidence with 25% poor, 67% fair and 8% good quality. The 
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quality of most of physical interventions studies were found 
to be limited by the absence of randomisation and blinding 
which were difficult to achieve due to ethical and practical 
reasons, respectively. Also, many studies were not controlled, 
comparing baseline with post-intervention measures, making 
item 2 (allocation concealment) and item 9 (intention-to-
treat analysis) not applicable.
Conclusions
To summarise, this review article has discussed the 
aetiology, development and consequences of bone loss in 
people with SCI. Furthermore, the most commonly used 
imaging modalities to assess bone loss after SCI and available 
therapeutic approaches have been evaluated.
It is clear that bone loss that develops in the paralysed 
limbs after SCI is highly site-specific, progressing with 
different patterns and timelines in cortical and trabecular 
bone compartments. In addition, rates of bone loss differ 
substantially between individuals but to date there is 
little understanding of the mechanisms responsible for 
this variation. Most of the physical and pharmacological 
interventions developed and evaluated to date appear to 
have a limited effect on bone health, but the poor quality 
of published studies in this area limits our ability to draw 
clear conclusions. More high-quality observational and 
interventional studies, with appropriate outcome measures 
targeting fracture-prone site, are needed.
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